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ABSTRACT 
 
Primary tumor extermination and conventional chemotherapy are proved to be inefficient in 
cancer therapy in that they preferentially abolish differentiated cells whilst leaving behind 
treatment resistant, tumorigenic cancer stem cells (CSCs). CSCs are validated to be the root 
cause of therapeutic resistance, recurrence, and tumor progression. CSCs are considered to be 
modulated by overexpression of certain pathways, including signal transducer and activator of 
transcription 3 (STAT3). The aberrant activity of STAT3 has been identified in clinical 
inspection of > 70% of breast and prostate cancer and its inhibition by various mechanisms holds 
unprecedented significance in modern medicine. Niclosamide (Nic), an FDA approved 
anthelmintic drug, has recently been reported as potent inhibitor of STAT3 and it is seen to 
trigger the activation of cancer cell apoptotic mechanism. Despite its promising cancer treatment 
capabilities, lack of solubility is a major bottleneck limiting its bio-availability. To circumvent 
the issue, we adopted a nanomedicine approach integrated with a surface decorated cucurbituril 
(CB[6]) host-guest chemistry using luminescent carbon nanoparticles (Nano-Carbobitaceae) for 
sustained and enhanced delivery of niclosamide traceable with vibrational spectroscopic 
methods. Carbon nanoparticles (Hydrodynamic dynamic size=55±1 nm) were obtained via the 
environmentally benign hydrothermal synthetic route using food grade Agave nectar as the 
carbohydrate source. The particles were either prefunctionalized (hydrodynamic dynamic size= 
76±13 nm) or postfunctionalized (hydrodynamic dynamic size= 93±4 nm) with CB[6] and were 
further loaded with STAT3 inhibitor Nic. Extensive physiochemical characterizations were 
subsequently carried out to confirm the binding of Nic and CB. FTIR results indicated a 2:3 
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complexation model. Furthermore, the 1H NMR results showed shifts in the characteristic peaks 
of Nic upon encapsulation in CB[6] cavity.   
The potential of the developed particle for the in vitro applications was evaluated. Interestingly, 
the hydrodynamic size of the particles was mostly preserved in various physiologically relevant 
media. Approximately two- fold enhancement in IC50 values were observed for the encapsulated 
drug versus free drug. The IC50 value of Nic, CB[6] Nic and CB[6] CNP Nic (post 
functionalized) was determined to be (45±04)×10-6 M, (28±03)×10-6 M and (21±02)×10-6 M, 
respectively. Our results indicated that this novel nanoplatform holds promise for sustained and 
enhanced chemotherapeutic delivery of sparingly soluble Nic for modulation of stem cell 
signaling pathways.     
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CHAPTER 1 
INTRODUCTION 
 
1.1 CANCER STEM CELL THEORY 
Cancer poses a death toll of ~8.2 million people every year. In the United States alone a total of 
1,658,370 new cancer cases and 589,430 cancer deaths are predicted to occur in 2015. Although 
cancer is currently the second most vicious disease after cardiovascular disease in the US, it is 
envisioned that the death burden would soon surpass that of heart disease in coming years [1]. 
Common methods of therapy such as primary tumor excision, chemotherapy and radiotherapy 
are usually partially successful in reviving the patient as there is a high probability of tumor 
relapse. The conventional therapy only preferentially abolishes differentiated cells whilst leaving 
behind small self- renewing, tumorigenic population of cells called “cancer stem cells” (CSCs) 
which show resistance to treatment [2].  
The emerging theory of CSCs came into vogue after the pioneering work of Dick and 
colleagues in the context of hematological malignancies [3, 4]. The model postulates that tumors 
are arranged in cellular hierarchy of heterogeneous cell populations with various molecular 
profiles as a result of the presence of small sub population of malignant cells coined as “cancer 
stem cells” (CSC) or “tumor initiating cells” (TICs) [5, 6]. The inherent phenotype of this 
subpopulation is that they share common attributes of normal tissue stem cells and they are 
capable of renewing themselves via symmetric or asymmetric cell division and also indefinitely 
differentiate to give rise to malignant tumors [7]. They are also known to exhibit plasticity in that 
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they reversibly switch between the stem and non- stem cell characteristics [8]. CSCs have been 
reported to be invariably occur in various human solid tumors namely, breast [9], colon [10] and 
brain [11].         
The hallmark quality of CSC is the expression of specific surface markers. For instance, 
in the case of breast cancer initiating cells, four surface antigen profile namely CD44, CD24 
(adhesion molecules), B38.1 (breast/ ovarian cancer specific marker) and ESA (epithelial 
specific antigen) have initially been identified by Al- Hajj et al. as the main biomarkers of the 
CSCs [9]. The contribution from these factors was such that all the immunodeficient mice with 
CD44+, B38.1+ or CD24-/low injection established palpable tumors in twelve weeks which was 
contrasting the CD44-, B38.1-, or CD24+ injection receiving mice. Table 1.1 summarizes the 
main biomarkers in distinguishing the CSC population. In addition to the aforementioned 
screening method, other methods such as flow cytometric evaluation of side population cells 
based on reduced uptake of Hoechst 33342 DNA binding dye [12] and aldefluor™ assay [13] 
hold prominence.       
As opposed to the former theory, another parallel model under the title of “clonal 
evolution model” exists. It follows the same principle as the Darwinian approach towards 
evolution and it states cancer progression is the consequence of the selection of the fittest variant. 
All of the differentiated cells in the clone have the capability of acquiring sufficient bias on the 
DNA sequence level so as to mutate and become metastatic while others become quiescent [14-
16]. The authenticity of both hypotheses is highly debatable and it is not clear which model has 
more robust ground in describing the aggressive behavior of cancer. Figure 1.1 compares and 
contrasts the two proposed models of tumor growth.          
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Table 1.1 Biomarkers in the detection of cancer stem cell subpopulation. Reproduced with permission from Ref. 
[17] 
Marker Description Marker Description 
CD24 Heat Stable Antigen, luminal CD31 Endothelial marker 
CD29 Beta 1 integrin Ter119 Hematopoietic marker 
CD44 Hyaluronic acid receptor CD140a Stromal marker 
CD49f Alpha 6 integrin CD133 Prominin-1 
CD326 
Epithelial surface antigen (ESA), 
EpCam 
CD201 PROCR, protein C receptor 
CD45 Hematopoietic marker CD166 
Activated leukocyte cell adhesion 
molecule (ALCAM) 
 
 
Figure 1. 1 Various models of tumor growth. Reproduced with the permission from Ref. [18]. 
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CSCs are resisting towards anti neoplastic therapy through various defense routes which 
can be narrowed down into two major groups: CSC- intrinsic and CSC- extrinsic [19]. The 
former is attributed to the DNA repair pathways [20], drug pump expression [21] and cell cycle 
alteration [19] while the latter is mostly concerned with the role of tumor microenvironment 
[22]. Similar to the normal stem cells, CSCs are thought to be residing in a microenvironment 
known as CSC niche which mediates the stemness, proliferation and immortality of stem cells 
[23]. Niche is distinguishable in their microenvironment in terms of anatomy which consists of 
fibroblasts cells, endothelial cells, immune cells and growth factors. CSC niche, on the other 
hand, accompanies the non- malignant cell population as well as pathogenic cells which release 
factors contributing to the angiogenesis and the promotion of tumor cell metastasis [24-26]. 
Additionally, the niche also has the responsibility to protect the cells from the invasion of 
genotoxic agents, a factor that justifies the CSC resistance towards therapy [23]. Not only does 
CSC niche sustain the immortality and self- renewal of these subsets but it also elicits them with 
the capability to induce epithelial-mesenchymal transition (EMT), a process known to be 
involved in tumor progression [27]. There is a well-established link between EMT and the 
abundance of inflammatory cues (e.g. IL-6, IL-8, TGF-b1, NF- B, TNFa and HIF-1) in the CSC 
microenvironment. The activation of inflammatory molecules, in turn, results in the activation of 
downstream self- renewal pathways such as JAK/STAT, NOTCH, MAP-Kinase/ERK, the 
PI3K/AKT, NF-ҡB, Wnt and TGFβ which regulate CSCs [28]. Therefore, over the past years 
there has been a paradigm shift towards the novel cancer treatment methods that specifically 
target the aforementioned pathways to fully combat cancer. 
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1.2 ROLE OF JANUS-KINASE (JAK)/ SIGNAL TRANSDUCER AND ACTIVATOR OF 
TRANSCRIPTION (STAT) PATHWAY IN TUMORIGENESIS 
As already mentioned, one of the common cytokine signaling pathway is Janus-Kinase (JAK)/ 
Signal Transducer and Activator of Transcription (STAT) pathway which was discovered in the 
context of interferon-α (IFNα)-, IFNγ- and intereukin-6 (IL-6)- mediated downstream signaling 
[29]. STAT family which consists of seven members (i.e. STAT1, 2, 3, 4, 5a, 5b and 6) are the 
latent cytoplasmic proteins which function as signal messengers and transcription factors. 
Besides, they contribute to the normal cell responses to the cytokines and growth factors [30]. 
STATs are involved in numerous physiological activities due to regulation of many genes 
including the genes involved in cell cycle progression, cell survival, differentiation, metastasis, 
apoptosis, angiogenesis and immune responses [31]. STAT activation begins with the 
dimerization of cell surface receptors upon the attachment of cytokines which leads to the 
activation of JAK tyrosine kinases. In the next step, the docking sites for the SH2- domains 
which are dominant in all STATs are created due to the phosphorylation of the residual tyrosine 
on the receptor. Subsequently, the receptor- bound STAT is phosphorylated by JAKs and 
translocate to the nucleus where they activate the transcription regulation of variety of genes. 
Another suggested mechanism is the activation of STATs in response to growth factors such as 
epidermal and platelet- derived, hepatocyte growth factors [32-34]. The signaling cascade is 
demonstrated in Figure 1.2. 
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Figure 1. 2 JAK/STAT signaling pathway. 
Of particular interest in the STAT protein family are the STAT3 and STAT5 whose role 
are prominent in cancer progression [35]. Considering the precise function of STAT3 in 
regulating cell functions, its aberrant activity would lead to devastating consequences; their 
pivotal role in transducing signal from several receptor and non- receptor tyrosine kinases 
activated in cancer cells has already been identified [36]. The first evidence highlighting the role 
of STAT3 activation in cancer cell was demonstrated in multiple myeloma where the apoptosis 
was effectively suppressed as a result of anti- apoptotic proteins Bcl-xL [37]. Later, it was 
discovered that STAT3 is constantly regulating the essential proteins for cancer cell sustention 
such as c-Myc [38], Cylin D1 [39] and Survivin [40] in human cancer cells. Subsequently, the 
activation of STAT3 protein has been observed in several cancers such as breast [41], lung [42], 
colorectal [43], esophageal [44], bladder [45, 46] and prostate [47]. Intriguingly, clinical data 
shows that STAT3 is persistently active in greater than 70% of prostate and breast cancer cells 
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[48]. More recently, the role of STAT3 has been linked to the CSC expansion and maintenance. 
Examples include the cooperation of STA3 in breast CSC [49], liver cancer [50], glioblastoma 
[51] and bone sarcomas [52].  
Considering the high correlation level between aberrant activity of STAT3 and human 
tumors prognosis, it is promising to engineer therapeutic approaches that specifically inhibit this 
particular pathway in combating cancer. Therefore, strategies have been developed to inhibit 
these pathways each of which functioning at a particular level, including the tyrosine- 
phosphorylation step for the activation of STAT3, DNA binding, association with other 
transcriptional co- activator, RNA inhibition and modulation of upstream regulators [53, 54]. 
Due to the extensive redundancy among cytokines, the most effective method is considered to be 
directly targeting STAT3 protein through NH2- terminal, DNA binding, and SH2 domains [55]. 
For instance, SH2 domain is considered as an appropriate target for blocking the STAT3 
dimerization by peptides, peptidomimetics and small molecule inhibitors [54]. Other chemical 
includes natural compounds and their derivatives namely curcumin, curcubitacins, indirubin and 
platinum complexes [55]. Recently, niclosamide has been regarded a drug for effectively 
suppressing the activity of this pathway [56].     
1.3 TARGETING STAT3 PATHWAY: NICLOSAMIDE 
Niclosamide (Nic) with the systemic name of (5-chloro-N-2-chloro-4-nitrophenyl)-2 
hydroxybenzamide (C13H8Cl2N2O4, MW: 327.119) (Figure 1.3), is an FDA approved small- 
molecule anti- helminthic drug for the treatment of human gastrointestinal tapeworm via oral 
administration and has been in market for approximately 50 years [57, 58].  
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Figure 1. 3 Molecular structure of niclosamide. 
It has been suggested that Nic’s anthelminthic effects are exerted through the inhibition 
of oxidative phosphorylation leading to the stimulation of adenosine triphosphatase in the 
mitochondria of tapeworm. This process subsequently debilitates the scolex and proximal 
segments of tapeworm both in vivo and in vitro [59]. Niclosamide has also been successfully 
applied as molluscicide for water treatment in schistosomiasis control program and has 
effectively functioned against severe acute respiratory syndrome (SARS) virus [60, 61]. Over the 
last five years, researchers have acknowledged the anti- neoplastic properties of the drug and its 
potential application in effective treatment of cancer [56]. The motivation behind the 
development of cancer drug based on a non-cancer drug originates from the fact that many 
diseases share common molecular and cellular pathways [62]. The superiority of the 
repositioning of an already FDA- approved drug is that it drastically reduces the cost burden of 
inventing new formulation considering that the drug development requires an average of 11 
years of research and investment of US $1.8 billion to translate the new agent from bench to 
bedside [62]. Generally, for a drug to receive FDA approval, the drug has to pass phase III 
clinical trial stage in addition to extensive research on cell and animal models [63]. Moreover, 
the existing drug has well- defined pharmacokinetics and safety profile in human application for 
decades. As a result of this, a preclinical and phase I study proposed in this work is highly 
appropriate. With a successful outcome, the drug can be swiftly translated to phase II and III 
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clinical studies [64]. Interestingly enough, Nic exhibits the inhibitory effects towards the 
pathways modulated in CSCs namely, Wnt/β-catenin [65, 66], mTORC1 [67], STAT3 [56, 68, 
69], NF-κB [70] and Notch [71]. For instance, Wang et al. [72] utilized high throughput drug 
screening methods to investigate the effect of candidate formulation on the extracted stem like 
side population (SP) breast cancer both in vivo and in vitro. In this research, niclosamide was 
rendered to down regulate the stem pathways such as Wnt/β-catenin, Notch, Hedgehog and 
induced apoptosis in the breast cancer cells. Furthermore, in vivo studies corroborated the 
therapeutic efficiency of the drug. In the same vein, out of the 1,200 clinically available 
formulations tested for the inhibition of stem like ovarian tumor- initiating cells (OTIC), Nic 
constitutively exhibited superior selectively towards CSC subpopulation both in vivo and in vitro 
[73]. The authors claimed that Nic is perturbing the metabolic pathway essential for biogenesis 
and redox regulation. Specifically, the potent inhibitory effects of Nic towards the STAT3 
pathway are attributed to the disruption of transcriptional activities due to phosphorylation 
abrogation and nuclear translocation of STAT3. Inhibition of STAT3- mediated stem cell marker 
OCT-4 through the application of Nic has been achieved by Kim et al. in MDA- MB-231 cells 
[74]. Furthermore, through a synergistic approach, Nic inhibited STAT3 phosphorylation and 
resulted in sensitization of human head and neck cancer cells to Erlotinib treatment [75]. This 
combinatorial approach effectively suppressed the epidermal growth factor receptor highly 
overexpressed in the human head and neck.  
Despite the promising cancer treatment capabilities, lack of aqueous solubility is a major 
drawback limiting the bio-availability of Nic. It is reported that the oral bioavailability of Nic in 
Sprague-Dawley rats is only 10% [76]. In fact, the drug is virtually insoluble in water with a 
solubility window of 5-8 mg/l at 20 ºC yet its solubility increases upon the pH increase. Several 
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strategies have been employed in order to combat this obstacle; amongst which are the 
encapsulation of the drug in the PAMAM dendrimers and cyclodextrins (HP-β-CD, β-CD) [77], 
preparation of solid dispersion with PEG6000 [78], synthesis of a water soluble analog – 
phosphate of niclosamide (p- niclosamide) [70] and very recently the use of rigid core micelles 
as an effective nanoscale strategy by our group [79]. While these approaches indeed offered 
some advantages, their potential for clinical translation has not fully been realized yet.  
1.4 SUPRAMOLECULAR CHEMISTRY 
Supramolecular chemistry or the “chemistry beyond the molecule” examines the interaction 
between several molecules and the induced properties as a result of that interaction. The interests 
on the structure and amazing abilities of enzyme was the cornerstone for the introduction of this 
relatively new field [80]. The field gained such a huge popularity that in 1987 the Nobel Prize in 
chemistry was endowed to Lehn, Pederson and Cram “for syntheses of molecules that mimic 
important biological processes”. The dynamic realm of supramolecular chemistry encompasses 
host-guest chemistry, molecular self-assembly, mechanically-interlocked molecular architectures 
and dynamic covalent chemistry [81].  
The forces in the supramolecular chemistry are of paramount importance and are non- 
covalent in nature. The non- covalent forces can further be classified into electrostatic interaction 
(i.e. ion- ion, dipole- dipole and ion- dipole interactions), hydrogen bonding, π- interactions (π-π 
stacking, anion- and cation - π interactions), van der Waals bonding and hydrophobic effects). A 
myriad of research interests have been attracted towards the host- guest chemistry which 
involved a binding phenomenon between a large molecule, coined as host, and a small molecule 
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called guest.The host molecule is in the form of cavitand1 allowing the reception of a guest 
molecule. The common host molecules are cyclodextrins [82], calixarenes [83], pillararenes [84], 
cucurbiturils [85], metallacrowns [86], crown ethers [87] and cryptophanes [88]. The structure of 
some of the host molecules are demonstrated in Figure 1.4. 
The implication of the weak association of host and guest molecule, due to the inherent 
nature of non-covalent interaction, is the reversible binding of the reaction constituents. This 
extraordinary property has been extensively exploited in molecular switches [89, 90], drug 
delivery [91, 92], catalysis [93, 94], dye tuning [95, 96] and in enzyme interaction [97, 98].  
A key feature of the host is its tendency to accommodate specific guest molecules with 
complementary properties (size, binding type, size, etc.) due to conformation constraints which is 
known as selectivity. Upon the introduction of an external stimulus, the structure can reorganize 
itself towards more thermodynamically stable state. This capability is utilized in stimuli- 
responsive functional materials.  
 
 
   
Figure 1. 4 The structure of some common guests: a) α cyclodextrin, b) calix[4]arene, c) pillararenes d) 
cucurbiturils. 
 
                                                          
1 Container shaped molecule 
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1.5 CUCURBITURILS 
Cucurbit[n]urils (CB[n]) are a family of cyclic oligomers resembling Cucurbitaceae (the Latin 
word for pumpkin). Although CBs were initially derived in 1905 through the condensation of 
glycoluril and formaldehyde under acidic conditions, its chemical structure remained largely 
unknown until 1981 when Mock and coworkers characterized the structure by NMR and IR 
spectroscopy [99]. It was revealed that the structure consists of macrocyclic hexamer glycoluril 
joined together with methylene bridges (CB[6]) [99]. Afterwards, other homologues of CB were 
introduced and the family expanded to include CB[5], CB[7], CB[8] and CB[10]. CB are barrel- 
like structures with two hydrophilic portals lined ureido carbonyl rims and a hydrophobic cavity 
which enable the encapsulation of neutral molecules and positively charged species through ion- 
dipole interaction. In addition, another mode of interaction is the hydrogen bonding between 
protonated molecules and negatively charged carbonyl ring. The cavity depth of CBs is 0.91 nm 
and the cavity sizes of CB[6], CB[7], and CB[8] correspond to α-, β-, and γ-CD, respectively 
where the sizes are provided in Table 1.2 [100]. While the overall properties of CBs are closely 
analogous to those of calixarenes and cyclodextrins, the presence of two linkers holding subunits 
together imparts it with improved structural rigidity, high degree of preorganization and superior 
binding selectivity. Extremely high binding affinities as high as 7.2 × 1017  M-1 has been reported 
for CB guest complex which is comparable to avidin-biotin pairs [101]. The comparison of the 
properties of different homologues of CB has been summarized in Table 1.2.   
Supramolecular host molecules such as cyclodextrins are orally and topically 
administered in clinical settings for drug delivery purposes. If cyclodextrins enter body in the 
non metabolized state they would be nephrotoxic. The poor selectivity of CD leads to usage of 
higher doses of cyclodextrin- containing formulations and boosts the chance for leaving CD 
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unmetabolized resulting in nephrogenic symptoms [102]. Nevertheless, the unique merits of CB 
have made it a promising unrivaled candidate for next generation targeted drug delivery systems.  
Amongst its various desirable properties, one can allude to the cytotoxic safety of CB, rendering 
its potential for biological- based purposes [103]. For instance, (4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) colorimetric cell viability assay in Chinese Hamster Ovary 
cells (CHO-K1) revealed no cytotoxicity at dosage up to 1 mM (IC50=0.53 mM) after 48 h of 
incubation [104]. Furthermore, no appreciable internal damage to the cell membrane was 
observable in fluorescent assessment of CB internalization, implying the appropriateness of CB 
for in vitro and in vivo applications. Intravenous administration of CB further corroborated that 
CB is well- tolerated (up to 200 mg.kg−1) and induces no acute toxicity in mice. In another study, 
the cytotoxicity, uptake and bioavailability of CB and its derivate have been investigated. High 
cell tolerance (up to 1 mM) and efficient cellular uptake was reported [105].  
One of the biggest challenges with hydrophobic drugs is their poor aqueous solubility 
leading to low bioavailability. In fact more than half of the newly developed chemical drugs 
suffer from low solubility despite showing promise in cancer therapy, hence hindering their 
applications [106, 107]. Interestingly enough, host-induced guest solubilization can mitigate this 
obstacle where the enhanced effect is mostly appreciable in drug delivery to bodily fluids rich in 
salt and acid [92]. For instance, it has been shown that benzimidazole- based drugs show 
enhanced bioavailability in the presence of CB[7] which is due to the “host- induced guest 
protonation” [108]. The drug possesses significant solubility in protonated state. Through 
binding with CB[7], the pKa values of the conjugate acid is enhanced by 2-4 units which implies 
the stabilization of the protonated form of the drug, thus increasing solubility. Similarly the 
solubility of camptothecin (CPT), an FDA approved DNA enzyme topoisomerase I (topo I) 
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inhibitor, was enhanced up to 0.4 and 47 µM in the presence of CB[7] and CB[8], respectively 
[109]. Furthermore, the photostabilization of the drug has also been reported as a result of CB 
encapsulation [108]. CB also assisted in maintaining the amorphous structure of the drug while 
preventing polymorph interconversion [110]. Perhaps the most distinctive feature of CB in drug 
delivery is drug stabilization owning to the shielding effects towards the guest which makes the 
formulation less prone to nucleophilic attacks in the bulk of the solution. Specifically, extensive 
research has been carried out on platinum- based anti- neoplastic agents [111-113]. The issue 
with the platinum (Pt)- based drugs is the high reactivity of chloride, carboxylate and ammine 
ligands in the formulation towards peptides and plasma proteins with thiol functionalities which 
will lead to drug inactivation. It was realized that the encapsulation of the drug by CB can block 
the nucleophilic attack by exerting steric hindrance [111]. In addition, due to the binding of CB 
to the hydrophobic part of the ligands, the platinum metal is placed near the portals of CB thus 
further helping the protection [103]. Later cisplatin was taken to demonstrate the effect of CB on 
the potency of the drug [111]. The in vitro cytotoxicity indicated no significant difference 
between the free drug and CB- encapsulated drug on the human ovarian carcinoma cell line 
A2780 and its cisplatin- resistant subunit A270/cp70 tumors and MCP1. Intriguingly though, the 
in vivo results from CB-cisplatin complex showed significant enhancement in suppressing the 
tumor growth compared to cisplatin on human tumor xenograft. The authors simply attributed 
the observation to the pharmacokinetic effects where CB promotes the total circulating cisplatin 
over the period of 24 h and suppresses drug resistance. In conclusion, CB is highly regarded as a 
promising drug carrier considering all its properties combined.  
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Table 1. 2 General structural parameters and properties of Cucurbit[n]uril family (Average dimensions are 
determined from the crystal structure with the CCDC code COQWOV [114]) 
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1.6 CARBON NANOSPHERES 
Since the introduction of fullerene, other classes of carbon nanomaterials such as carbon 
nanotubes (CNTs) [115], graphene [116], nanodiamonds [117], carbon dots [118] and very 
recently nanothread [119], have generated a plethora of research interest amongst scientists due 
to their favorable properties that make them suitable for applications in composites, electronics, 
photonics and biomedicine. Of particular interest in this expanding family is the fascinating class 
of carbonaceous nanomaterials denoted as carbon nanodots also known as carbon quantum dots 
or simply carbon dots (CDs). It is important to demarcate the difference between carbon dots and 
graphene dots despite their similarity in chemical and physical properties in many aspects. The 
difference, though, stems from their size and their synthetic routes, where graphene dots have 
lateral sizes up to 100 nm and are commonly obtained from graphene based precursor whereas 
CDs refer to particles with aspect ratio of 1 and below 10 nm in diameter [120]. In 2004, 
fluorescent CDs were discovered by serendipity through the process of purifying single walled 
carbon nanotubes (SWCNT) via arch discharge method [121]. The abundance of surface 
functional groups such as carbonyl, carboxyl, epoxy, amino, and hydroxyl endow CDs with high 
aqueous solubility [118]. Moreover, their nearly spherical shape, simplicity of surface 
functionalization and facile synthetic routes are amongst the attributes that offer superiority over 
the rest of the carbon nanomaterials family. In general, the synthetic routes of CD can be divided 
into bottom-up and top-down approaches and include methods such as laser ablation [122], 
microwave pyrolysis [123], hydrothermal treatment [124] and electrochemical reduction [125]. 
Versatile precursors have been tried for the synthesis of the CDs such as glucose [126], glycerol 
[127], candle soot [127], orange juice [128], banana juice [129], tea [130], caramel [131] or in 
17 
 
Nescafe®coffee [132], molasses [133] and honey [134] indicating the ease of production and the 
potential of scale- up fabrication of these nanoparticles. 
In the past few years, extensive research has been directed to exploit the luminescence 
properties of CDs which is urged by the demands in the progressive field of optical imaging. 
These particles are overtaking semiconductor quantum dots by virtue of excellent 
biocompatibility as opposed to the potential cytotoxicity of QDs due to the presence of heavy 
metals [135]. In addition, they surpass organic dyes in photostability and high quantum yield as 
well as not indicating photobleaching and blinking [136]. The fluorescent properties of CDs are 
mainly dependent on the synthetic method and the type of surface passivation. Extensive 
research has been conducted to demonstrate the mechanism of fluorescence in CDs; although 
there are still large controversies regarding the origin of the phenomenon. The two predominant 
proposed mechanisms include the radiative recombination of surface confined electrons and 
holes leading to the creation of excitons and quantum confinement of emissive deep energy traps 
which become more emissive upon the astute choice of surface passivation method [137]. 
Despite the lack of knowledge about the radiation mechanism, CDs have already been exploited 
for in vitro and in vivo fluorescent imaging [138], Raman imaging [139], photoacoustic imaging 
[140] and photosensitizing for photodynamic therapy [141]. For instance, Sun’s group reported 
on the potential of CD in two- photon luminescence microscopy in MCF-7 (human breast 
cancer) cell line [142]. Furthermore, HepG-2 (human liver carcinoma) cells have been incubated 
with CDs and subsequently were imaged. Cell internalization of CDs was observed by confocal 
microscopy or even common fluorescence microscopy. Hsu et al. [143], used LLC-PK1 (pig 
kidney cell line) to elucidate the applicability of CDs for cell imaging. It was plausible that cells 
internalized CDs by endocytosis pathway. Upon excitation at long wavelength, red fluorescence 
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signal was detectable. The photostability of CD was demonstrated to be remarkably high without 
exerting prominent cytotoxic effects.  
Photoacoustic (PA) imaging, as a hybrid imaging modality, enjoys the merits of both 
optical and ultrasound imaging for deep tissue penetration as well as high spatial resolution 
[144]. An ideal contrast agent for PA imaging should meet some criteria such as high photon 
absorbance and efficient ability to convert light to heat [137]. In this regard, our group did a 
pioneering research on CD applications [140]. Specifically, they exploited the honey derived CD 
as contrast agent for PA imaging of sentinel lymph node to monitor the cancer staging in a real-
time manner. The CD had reasonable lymphatic transport rate and also contributed to >9 fold 
enhancement in the PA signal over the rat’s blood suggesting the potential of CDs as contrast 
agents for PA imaging during intraoperative SLN biopsy intervention. Overall, these studies 
corroborated the promise of CD as efficient optical nanoprobes.   
1.7 EVALUATION OF THE CYTOTOXICITY OF CARBON NANOSPHERES 
Thorough studies on the toxicity of CDs are desired before their translation into the clinic. Based 
on the current assessment of the data in literature, it is quite established that CDs are generally 
nontoxic and in some studies it was shown that the surface passivizing polymer worsened its 
toxicity profile [145, 146]. 
As already disucssed, CDs surpass their QD counterparts in biocompatibility. In a recent 
study, the relative toxicity of three pristine nanomaterials were examined [147]. It was realized 
that toxicity of QDs>>Au nanoparticles>C-dots with IC50 values for normal NIH/3T3 (Mouse 
embryonic fibroblast) cells as 0.98, 62, and 250 μg.ml-1, respectively. 
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MTT and Trypan blue assay were utilized on HepG2 cells to evaluate the cytotoxic effect of CDs 
during 24 h incubation [148]. The cell viability upon exposure to 0.5 mg. ml-1 ranged between 
90-100%. The concentration was increased to values as high as 102 and 103 times more than the 
dose required for bioimaging, suggesting the minimal toxicity for bioimaging. In addition, Sun et 
al., explored the in vitro and in vivo cytotoxicity of CDs [149]. MTT results revealed >80% cell 
viability for CD in MCF-7 for concentration of 0.1 mg.ml-1. The in vivo results using CD-1 mice 
demonstrated that after 4 weeks of intravenous administration of CDs, no mice suffered from 
adverse clinical signs including anorexia, hair loss, scab, vomiting, or diarrhea. The bodies’ 
normal functions were not impaired compared to control group and was maintained at similar 
level irrespective of the dosage and time indicating no cytotoxicity. Although analysis of 
harvested tissue showed the presence of CDs in liver, spleen and kidneys, the level of 
accumulation was minor. Furthermore, Yang et al. [149] conducted a study on CD-1 mice for 
over 90 days. No mortality, lesion, or considerable weight change was observed at the dosage of 
20 mg.kg-1. In a more recent study, athymic nude mice bearing subcutaneous SCC7 tumors, were 
exposed to CDs conjugated to NIR dye to track the fate of the CDs in vivo [150]. The 
nanoparticles were administered via three routes namely, intravenous (IV), subcutaneous (SC), 
and intramuscular (IM). All three routes were appropriate for the clearance of CDs, with IV 
being the fastest pathway. The system underwent rapid clearance, yet passive tumor targeting. 
The prime clearance route was through the kidney. Besides, reticuloendothelial system (RES) 
evaluation indicated the minimal uptake of particles by this route and rendered improved tumor 
to background ratio. Furthermore, tumor accumulation was higher in SC and IV injection than 
IM injection. In a nutshell, the toxicity of CD can be considered very low and cytotoxicity, if 
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any, would be exerted through surface functionalization which can be reduced by the appropriate 
choice of passivation agent.    
1.8 CARBON NANOSPHERES IN DRUG AND GENE DELIVERY 
CDs can also serve as a platform for controlled drug and gene delivery due to their high surface 
to area ratio, excellent biocompatibility, small size for being taken up by solid tumors and most 
importantly, being rich in surface functional moieties appropriate for the incorporation of various 
compounds for targeting strategies. These features combined with their bioimaging potentials 
have turned them into promising “theranostic” candidates. For instance, Zhou et al. [151], came 
up with a pH- responsive nanocomposites of CDs and mesoporous silica for drug delivery and 
optical imaging purposes. The Dox loaded CD gated nanocarrier exhibited enhanced efficacy in 
treating cancer cells as the cargo was efficiently taken up by the cancer cells through endocytosis 
pathway as has been confirmed by fluorescent microscopy. Moreover, the nanocomposite acted 
as non- invasive vehicle for in vitro and in vivo tracking of the therapeutic agent. Zheng et al. 
[152] reported on the multifunctional theranostic agent with the conjugation of a variant of anti- 
cancer drug oxaliplatin (Oxa) on the surface of CDs. The formulation of Oxa was changed such 
that it incorporated carboxyl groups to react with amino functionalities of CDs. MTT assessment 
of the nanoformulation on HepG2 cells revealed the IC50= 3.4 μg.ml–1. The nanocarrier manifests 
the ability in eradicating 82.4% of tumor size after three days in vivo after two doses of CD-Oxa 
(0.72 mg.ml-1 of Pt, 20 μl) in Chinese Kun Ming (KM) mice injected with hepatocarcinoma 22 
cell line (H22) liver cancer. In addition, during the course of treatment the drug can be traced due 
to fluorescent properties of CDs which helps customize the injection time and dosage of 
medication. Very recently, our group has reported on the application of luminescent carbon dots 
(LCN) for synchronized imaging and delivery of pentoxifylline (PTX), an anti-inflammatory 
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drug which has been repurposed for targeting melanoma [139]. The surface tuning of the 
particles was achieved either by PNIPAM polymer which was labeled as temperature responsive 
(TR-LCN) set or multiarm polyethylene glycol (MA-PEG) called MA-PEG-LCN. Two 
nanoparticle surface coatings were compared with each other in terms of therapeutic efficacy and 
release pattern. Thanks to the choice of coating, LCN could emit in NIR region which is the 
relevant imaging window for deep tissue penetration and prevention of autofluorescence from 
organs. After rigorous physiochemical characterization of the nanoformulations, the in vitro 
release behavior was inspected. The two delivery systems contrasted in drug release behavior in 
that the MA-PEG-LCN exhibited higher loading efficiency compared to TR-LCN. Moreover, the 
total drug release in MA-PEG-LCN particle was lower compared with TR-LCN. It was also 
realized that TR-LCN exhibited burst release at room temperature as opposed to gradual release 
at 37 ºC. The authors conjectured that the former can be utilized for immediate therapy purposes. 
Subsequently, incubation of C32 melanoma cells with MA-PEG-LCNs and TR-LCN was 
executed and the cells were observed using infrared and Raman imaging where it was shown that 
the two formulations treated their cargo differently. Although MA-PEG-LCN indicated 
ydistribution all over the cells, TR-LCNs adopted more selective localization. No significant 
difference was conceivable in the imaging ability of TR-LCNs and MA-PEG-LCNs, although 
the stimuli- responsiveness of TR-LCNs can be exploited for therapeutic and imaging purposes 
simultaneously. The author further utilized the unique properties of CDs for ex vivo fluorescence, 
NIR and Raman imaging on the pigskin. They could successfully image the TR-LCNs particles 
incubated in the pig skin where they observed homogenous destruction of the particles in the 
samples. Furthermore, as a proof of concept to show deep skin imaging in NIR region, pig skin 
treated with MA-PEG-LCNs were employed and they could localize signal at approximately 100 
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μm from the surface. Although similar experiment for TR-LCNs treated skin was impeded due to 
fluorescence quenching from the particles, it was concluded that the particles hold promise for 
further investigation in NIR imaging in vivo. Table 1.3 summarizes some of the researches 
executed using CDs as drug delivery, gene delivery or theranostic agent. 
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Table 1. 3 Recent advances in the application of carbon dots for theranostic applications. 
Reference Agent Application and Prominent Results 
Misra et al. 
[153] 
CDs-DNA complex (CNPLexe) was efficiently transfecting green fluorescent 
protein reporter gene containing pDNA. Higher cell viability of 
polyethylenimine (PEI) coated CDs compared with PEI was noticed.       
Hu et al. [154]  Branched polyethyleneimine-based carbon dots (PCD) are prepared from 
branched polyethyleneimine. The particles show potential for gene delivery 
and bioimaging as has been confirmed by gene transfection studies.  
Wang et al. 
[155] 
Hollow CDs were prepared from bovine serum albumin (BSA). Particles were 
ca. 6.8 nm in size with 2 nm pore size. DOX was loaded and its release showed 
pH triggered manner. The immediate uptake of the system was observed by 
bioimaging indicating their potential in biolabeling and cell tracking.    
Pandey et al. 
[156] 
CD on the surface of Gold nanorod (GNR) was employed for delivery of 
DOX. It was envisioned that the particles be applicable in drug delivery, 
photothermal therapy and biological imaging.        
Tang et al. 
[157] 
Direct and sensitive Förster resonance energy transfer (FRET)-based CD drug 
delivery system was reported to do real time monitoring of pH- mediated DOX 
release. CD dot was used as platform for drug delivery and as donor of FRET 
pair to be highly sensitive on the separation distance. Furthermore, two photon 
imaging of the system at tumor tissue level was tested.  
Chen et al. 
[141] 
Photodynamic therapy drug, Chlorin E6 (Ce6) was conjugated to CD for 
photodynamic therapy (PDT) and photosynthesizer fluorescent detection 
(PFD) of gastric cancer in vivo. It was demonstrated that the theranostic 
platform was successful for NIR imaging and represented good tumor- homing 
ability.      
Kim et al. 
[158] 
Fluorescent CD-PEI/Au-PEI/pDNA ternary nano-assembly was employed for 
probing the mechanism of association/ dissociation of polymeric 
carrier/plasmid DNA (pDNA) for efficient gene transfection. The probe was 
initially off due to quenching effect of Au on CDs. It was turned on upon ionic 
repulsion and Au-PEI disintegration under saline conditions.    
Zhou et al. 
[159] 
Multi-functional probe based on iron oxide nanocrystals and fluorescent 
carbon dots (CDs) were developed for MRI and fluorescent imaging. DOX 
was loaded so that the drug could serve as controlled chemotherapeutic agent. 
This alongside with the high tendency of CDs to convert NIR light to heat was 
employed for photothermal/ chemotherapy treatment.        
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CHAPTER 2 
SCOPES AND EXPERIMENTAL METHODS 
 
2.1 AIMS AND SCOPES 
Primary tumor extermination and conventional chemotherapy are proved to be inefficient in 
cancer therapy in that they preferentially abolish differentiated cells whilst leaving behind 
treatment resistant, tumorigenic cancer stem cells (CSCs). CSCs are validated to be the root 
cause of therapeutic resistance, recurrence, and tumor progression. CSCs are considered to be 
modulated by overexpression of certain pathways including signal transducer and activator of 
transcription 3 (STAT3). Niclosamide (Nic), an FDA approved anthelmintic drug, has recently 
been reported as potent inhibitor of STAT3 and triggered the activation of cancer cell apoptotic 
mechanism [79]. Despite its promising cancer treatment capabilities, lack of solubility is a major 
drawback limiting its bio-availability. To circumvent the issue, we adopted a nanomedicine 
approach integrated with host-guest chemistry for sustained and enhanced delivery of this 
antineaoplastic agent traceable with vibrational spectroscopic method. The aim of this research is 
the synthesis and characterization of next generation luminescent carbon nanoparticles coated 
with cucurbituril for the controlled delivery of Nic as STAT3 inhibitor. In addition these 
particles can be tracked down by FT-IR and Raman imaging techniques therefore enabling their 
theranostic applications. Extensive physiochemical characterization has been carried out to 
elucidate the behavior of Nic in the presence of CB[6] and CNP. In vitro studies have been 
carried out to investigate the potential of the developed formulation for the drug delivery 
applications. The complex formation of Nic with CB[6] with sustained release ability is reported 
for the first time. In addition, carbon nanoparticles coated CB[6] as the delivery platform for the 
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enhanced cellular uptake and translocation of anti- cancer agent is developed for the first time in 
this research.     
2.2 EXPERIMENTAL TECHNIQUES 
2.2.1 MATERIALS AND REAGENTS 
Food grade agave nectar was purchased from HoneyTree’s® Organic Agave Nectar, Onsted, MI. 
Cucurbit[6]uril (CB[6]) hydrate (CAS Number 80262-44-8, Empirical Formula C36H36N24O12 · 
xH2O) and Niclosamide, 98% (HPLC) (2',5-Dichloro-4'-nitrosalicylanilide, CAS Number 50-65-
7) was supplied from Sigma Aldrich (St. Louis, MO, USA) and AKA Scientific Inc. (Union City, 
CA, USA), respectively. Nanopure water (0.2 × 10−6 M, 18 MΩ cm) was used throughout the 
experiment unless otherwise stated. For biological assessments, human breast cancer MCF- 7 
cell line was obtained from American Type Culture Collection (ATCC) and was cultured using 
the prescribed instructions from the ATCC. High Glucose Dulbecco’s Modified Eagle’s Medium 
(DMEM; Sigma) was supplemented with 10% fetal bovine serum (FBS (Seradigm, US)) and 1% 
Penicillin Streptomycin (PenStrep) (Lonza) Trypsin (EDTA 0.02%, dextrose 0.05%, and trypsin 
0.1%) in Dulbecco’s phosphate buffer saline (DPBS, Gibco). Tetrazolium salt 3-[4,5-
dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide was prepared from Sigma. 1H NMR 
measurements were carried out in DMSO-d6 (Cambridge Isotope Laboratories, Inc., MA, USA) 
as the solvent. Other reagents were obtained from Aldrich Chemical Co. (St. Louis, MO) and 
were used without further purifications. 
2.2.2. PREPARATION OF NANO-CARBOBITACEAE 
Pristine carbon nanoparticles (CNP) were synthesized by facile hydrothermal method using 
commercially available food grade agave nectar as the carbohydrate source. Agave nectar 
dispersed in water (0.2 mg.ml-1) was slowly heated on a hotplate at 300 ºC (Corning®) so as to 
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evaporate water and the product visually changed color from amber to dark brown. 
Subsequently, the burnt residue was resuspended in water and probe- sonicated (Q700, Qsonica 
Sonicators, Newtown, CT) in the ice bath for 5 min at Pulsed Amp, 1; on, 5 s; off, 3 s. To obtain 
a narrow size distribution, the as synthesized nanoparticles were purified by dialysis cassettes 
using cellulosic membrane (10K MWCO, 3ml, Thermo Scientific, IL, USA) against nanopure 
(0.2 × 10−6 m) water for a prolonged period of time. Subsequently, the content underwent two 
steps of additional filtration (Acrodisc syringe) with mesh size of 0.45 µm and 0.22 µm, 
respectively.  
Two methods of synthesis were applied for CB[6] decorated CNPs. In the first method, 
CB[6] was introduced on the surface of CNP via vigorous stirring of the respective 
concentrations of CB[6] for 5 min using vortex machine. These particles are labeled CB CNP 
post functionalized henceforth. In the second method, one pot nucleation of CB[6] CNP was 
carried out. Briefly, the mixture of agave nectar and CB[6] suspended in water at the desired 
concentration was hot plated and similar steps as for CNP preparation was followed. These 
particles are denoted as CB CNP prefunctionalized. Comprehensive physiochemical 
characterization of the prepared nanoparticles was carried out.              
2.2.3 PREPARATION OF NANOFORMULATIONS 
Stock of Nic was prepared in ethanol (2 mM) and then diluted with water to reach the desired 
concentration. The drug was loaded in nano-carbobitaceae using simple mixing method for 5 
min.  
2.3 DYNAMIC LIGHT SCATTERING MEASUREMENTS 
The particles were mildly vortexed prior to size determination. The hydrodynamic size and the 
distribution of the nanoparticles was determined through dynamic light scattering measurements 
27 
 
on Malvern Zetasizer ZS90 instrument (Malvern Instruments Ltd, United Kingdom) at fixed 
angle of 90º. A photomultiplier aperture of 400 mm was used and the incident laser power was 
adjusted so as to obtain a photon counting rate between 200 and 300 kcps. The measurements 
whose measured and calculated baselines of the intensity autocorrelation function fell in +0.1% 
range were used to determine nanoparticle hydrodynamic diameter. The mean hydrodynamic 
diameter (Z-average) and polydispersity index (PDI) values were obtained based on the 
correlation function. PDI values below 0.3 are considered as unimodal size distribution with 0.2 
indicating the monodispersed nanoparticles. All measurements were carried out in triplet of 
twelve consecutive measurements. 
2.4 TRANSMISSION ELECTRON MICROSCOPY (TEM) 
Prior to sample preparation for TEM imaging, the nanoparticles were mildly vortexed. 10 µL of 
sample was drop cast on 200-mesh copper grid. After 1 min, excess fluid was absorbed by lint 
free Kim wipes. The transmission electron micrographs were acquired on a JEOL 2100 Cryo 
TEM machine and imaged by Gatan UltraScan 2k × 2k CCD camera. The same concentration of 
CB CNP prefunctionalized and CB CNP postfunctionalized were used. The anhydrous diameter 
was determined by making 100 random measurements of nanoparticles on image J software 
(NIH, Bethesda, MD, USA) and was reported as mean± standard deviation.      
 2.5 ATOMIC FORCE MICROSCOPY (AFM) 
An aliquot of nanoparticle suspension was placed on the top of freshly cleaved mica sheet 
attached to a stainless steel disc to minimize unwanted strains. Next, the specimens were vacuum 
dried overnight. AFM micrographs were obtained in the tapping mode on Asylum Cypher AFM 
device.        
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2.6 ELECTROPHORETIC POTENTIAL MEASUREMENTS 
Zeta potential ζ values were determined using a Malvern Zetasizer (Malvern Instruments Ltd, 
United Kingdom) of nano series. The experiment was performed at 25 ºC and at PH=7 at the 
light scattering mode in the phase analysis light scattering (PALS) mode following solution 
equilibration at 25 °C. Calculation of ζ from the measured nanoparticle electrophoretic mobility 
(μ) employed the Smoluchowski equation:  where ε and η are the dielectric constant 
and the absolute viscosity of the medium, respectively. Measurements of ζ were reproducible to 
within ±2 mV of the mean value given by 3 determinations of 15 data accumulations. 
2.7 UV-VIS SPECTROSCOPY 
Absorption spectra from different samples were recorded using GENESYS 10 UV-Vis 
spectrometer (Thermo Scientific, MA, USA). The samples were scanned in 220-800 nm range 
and the scan resolution was varied from 0.1-0.5 nm based on the requirements of the experiment. 
Experiments were carried out in 1cm plastic cuvettes with the covering wavelength range 
between 230-900 nm. Throughout all the experiments, the samples were diluted such that the 
solutions obeyed the Beer Lambert law to maintain highest accuracy. Concentration of a 
component of interest was determined based on carefully calibrated curves obtained by reading 
serial dilutions of the samples. 
2.8 FOURIER-TRANSFORM INFRARED (FTIR) SPECTROSCOPY 
As-synthesized particles were repeatedly applied to MirrIR IR-reflective glass slides (Kevley 
Technologies, Chesterland, OH, USA) to acquire IR spectra using a PerkinElmer Spotlight 400 
(PerkinElmer, Waltham, MA, USA) equipped with a thermal source, and a raster-scanning linear 
array detector. Spectra were collected using a 1 cm.s−1 mirror speed for acquisition, and zero 
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padding was not used. Background scans were taken at 8 cm−1 spectral resolution; 150 × 150 μm 
images were collected at 8 cm−1 spectral resolutions with 8 scans per pixel and a 6.25 × 6.25 μm 
pixel size. Data were atmosphere corrected on the spotlight and further processing was done 
using Matlab R2013 software. 
2.9 RAMAN SPECTROSCOPY  
Raman spectra were acquired on dried samples in reflection mode (LabRAM Horiba, as 
discussed above). The excitation wavelength for all measurements was 532 nm and the power 
was set to 25 mW at the sample with a 10 s acquisition time. The Raman shift from 400 to 4,000 
cm–1 was collected at 8 cm–1 spectral resolution. Laser light was focused through a 100×, NA 0.8 
objective into the sample plane and the scattering was collected in the reflection geometry using 
the spectrograph coupled with an Andor Newton back-illuminated EMCCD camera. 
2.10 TRACKING THE COMPLEX FORMATION BETWEEN CB[6] AND NIC 
2.10.1 STOICHIOMETRY OF THE REACTION 
For the determination of the stoichiometry of the complexation event, Job’s plot was constructed 
by plotting the amide peak wavenumber versus the mole fraction. The mole fraction of CB[6] 
was varied between 0 and 1 while keeping the total molar concentration constant at 0.5 mM. A 
total of 7 points were acquired for making the Job’s plot. The extremum was taken as the 
Stoichiometric ratio. 
2.10.2 UV-VIS TITRATION 
1 ml of Nic (0.02 mM) in the mixed ethanol/ water solvent (1%  v/v) was transferred to the UV-
Vis cuvettes. Subsequently, 10 µL of titrant containing CB (0.3 mM) and Nic (0.02 mM) was 
added to the cuvette and mixed for one min. After each addition, UV-Vis spectra were obtained. 
The absorbance at 340 nm was plotted against equivalent of CB (i.e. [CB]/[Nic]).    
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2.10.3 FLUORESCENCE TITRATION 
2D excitation, emission spectra were collected using a Horiba Aqualog Scanning 
Spectrofluorometer (Horiba scientific, Edison, NJ). 3000 µL of Nic (0.04 mM) was transferred to 
the cuvette and 2D excitation (240–700 nm) and emission (240-800 nm) contour was obtained at 
3 nm resolution. Contribution of solvent was subtracted using nanopure water as the blank 
sample. After each measurement, the first- order Rayleigh scattering was corrected and all 
spectra were normalized to 1 mg.l−1 quinine sulfate. Subsequently 30 µL of titrant containing Nic 
(0.04 mM) and CB[6] (0.6 mM) was added and mixed.            
2.10.4 1H NMR TITRATION 
1H NMR measurements were carried out on Varian VXR 500 spectrometer operating at 500 
MHz equipped with 5mm Nalorac QUAD probe. Chemical shifts were reported in ppm and 
referenced to the solvent proton impurities. DMSO-d6 was used as the deuterated solvent for all 
samples. 700 µl of Nic (2 mM) was transferred to the NMR tube. The temperature was raised to 
37 ºC so as to ensure accurate shimming. A total of 128 acquisitions were made. Then 10 µl of 
titrant containing CB (30 mM) and Nic (2 mM) was added at each step and the acquisition was 
made. The data was processed and analyzed with MestRenova™ 8.1 software (Mestrelab 
Research SL; Santiago de Compostela, Spain). 
2.10.5 MOLECULAR DYNAMIC SIMULATION 
The ReaxFF-based Molecular dynamic simulations were implemented in order to figure out the 
energy minimized state between CB[6] and Nic. ReaxFF is a general bond order based empirical 
force field method which allows bond breaking and formation during simulations. The energy 
term is the superimposition of several contributions as follows: 
Esystem = Ebond + Eover + Eunder + Elp + Eval + Etor + EvdWaals + ECoulomb 
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Where Ebond, Eover, Eunder, Elp, Eval, Etor, EvdWaal, ECoulomb are the energy contribution from bond, 
over-coordination penalty and undercoordination stability, lone pair, valence, and torsion, non-
bonded interactions van der Waals, and Coulomb energies, respectively. In this method, the 
partial charge of the individual atoms are determined based on the electronegativity equalization 
method (EEM) to provide the geometry- dependent charge distribution [160, 161]. The 
minimization was carried out at 1 K using ReaxFF force field.  
2.10.6 INTERACTION MONITORING BY ELECTROCHEMICAL MEASUREMENTS 
The electrochemical of CB[6] and Nic and the CB[6], Nic complex in solution were studied by 
cyclic voltammetry on Reference 600™ potentiostat (Gamry Instruments, Warminster, PA). The 
sweeping range was -0.3- 1.2 V at the scan rate of 10 mVS-1 and initial/final potential of -0.3/1.2 
V respectively. The stock of Nic in ethanol (2 mM) was diluted by phosphate buffer saline (0.1 
M, pH 7.4) to reach to the concentration of 0.05 mM. Similarly CB was dispersed PBS. The 
corresponding volumes of CB and Nic were vortexed to reach the desired concentration. The 
experiment was carried out at room temperature using gold macrodisc electrode as the working 
electrode. The data were referenced against Ag/AgCl electrode and platinum was chosen as the 
counter electrode. Prior to each set of experiment, open circuit potential (OCP) measurement 
were taken to assess the stability of the solutions.        
2.10.7 PH TITRATION TRACED BY UV-VIS SPECTROSCOPY  
To monitor the effect of CB[6] on the pKa value of Nic, pH titration study was adopted. Initially 
Nic (0.02 mM) was prepared in 100 ml of low pH water (adjusted by addition of HCl). The pH 
was carefully adjusted by concentrated aliquots of NaOH and 1 ml of sample at specific pH was 
taken. The absorbance profile was collected by UV-Vis spectroscopy machine. The same 
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procedure was followed for Nic (0.02 mM) in the presence of CB (0.2 mM). The concentration 
of CB was chosen so as to ensure the excess of CB.   
2.11 IN VITRO ASSESSMENTS: 
2.11.1 PARTICLE STABILITY UNDER PHYSIOLOGICALLY RELEVANT CONDITIONS 
Stability of the formulation was monitored over a period of 30 days by evaluating the 
hydrodynamic diameters at different time points. The particles were incubated at three different 
conditions namely, aqueous solution with pH=7.4, aqueous solution with pH 4.5 (to mimic 
cancer cell environment) and aqueous solution containing 10% FBS. The samples were kept in 
water bath cycled to 37 ºC and were taken out for DLS reading at the corresponding time 
intervals.    
2.11.2 DRUG LOADING EFFICIENCY 
The loading efficiency of Nic in CB[6] was calculated by measuring the concentration of 
unbound drug. The samples were vigorously centrifuged (Optima™ MAX-XP Ultracentrifuge, 
Beckman-Coulter, Brea, CA) for 10 minutes at 75,000 rpm. Subsequently, the supernatant was 
collected for further analysis. The concentration of the unbound drug was determined by UV-Vis 
analysis of the collected supernatant and interpolating the concentration on the constructed 
calibration curves of known Nic concentration. Following equation was utilized for loading 
percentage determination: 
% Loading efficiency= [(Loaded niclosamide– Unbound niclosamide)/Loaded 
niclosamide]*100. 
2.11.3 DRUG RELEASE KINETIC STUDY 
The in vitro drug release profile were monitored under various physiologically relevant 
conditions and prolonged for 120 hours. Specifically, three conditions were adopted: 1. pH=7.4, 
33 
 
25 ºC, 2. pH=4.5, 37 ºC, 3. pH=7.4, 37 ºC 4. Aqueous media, 10% FBS, 37 ºC (the experiment 
was hindered due to high inconsistency in the UV-Vis pattern). 1 ml of CB [6] (10-3 mM), CB 
[6] (10-3 mM) CNP (pre functionalized) and CB [6] (10-3 mM) CNP (post functionalized) 
containing 0.1 mM Nic was pipetted into a dialysis cassette (10K MWCO, 3ml, Thermo 
Scientific, IL, USA) and dipped into 100 ml of the media to simulate sink condition. The beaker 
was magnetically stirred to keep the conditions homogenous across the solution. At the specified 
time points, 1 ml of the sample was taken for further UV-Vis analysis. The media was 
supplemented with 1 ml of fresh media to maintain the volume. The concentration of the released 
load was determined using calibration curves.        
2.11.4 IN VITRO CELLULAR CYTOTOXICITY STUDIES 
Cell toxicity assay was performed on human breast cancer ER (+) MCF-7 (ATCC) cells. Cells 
were cultured in Dulbecco’s modified Eagle’s medium  supplemented with 10% fetal bovine 
serum (FBS) in T25 culture flasks (Cellstar; Germany) and were incubated at 37 °C in a 99% 
humidified atmosphere containing 5% CO2. Cells were regularly passaged by trypsinization with 
0.1% trypsin (EDTA 0.02%, dextrose 0.05%, and trypsin 0.1%) in DPBS (pH 7.4). 
Nonsynchronized cells were used for the experiments. 
2.11.5 CELL VIABILITY ASSESSMENTS 
The cell toxicity assay measures the potency of the drug in inhibiting the cell growth and 
compared by calculating IC50 (inhibitory concentration for 50% cell population). MCF-7 cells 
were seeded in the 96- well- tissue culture polystyrene plates with the density of 104 cells per 
well. After 24 h the cells were treated with the samples prepared in growth medium at various 
concentrations ranging from 1.5-50 µM. After 44 h of incubation, cells were imaged for bright 
field imaging to visualize the effect of treatments on cell growth density and changes in cellular 
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morphology. It was followed by addition of a 20 μl (5 mg.ml-1) solution of MTT to the growth 
medium while growing the cells. MTT turns into purple formazan after reduction by 
mitochondrial enzymes in living cells. MTT added cells were incubated for 4 h at 37 °C under 
5% CO2 atmosphere. The solution was removed and replaced by 200 µl of dimethyl sulfoxide 
(DMSO) added to each well and incubated for another 5 min. The solution was mixed by pipette 
in order to completely dissolve the dark blue crystals from the samples. Absorption was read on 
multi-well plate reader machine (BioTek Synergy HT, US) using the standard wavelengths of 
592 nm. An average of the triplicate wells were calculated and normalized by dividing to the 
value of control well, the standard error mean was calculated for each sample using software 
Graph pad prism 6.0. 
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CHAPTER 3 
RESULTS AND DISCUSSION 
 
3.1 PARTICLE SYNTHESIS AND GENERAL CHARACTERIZATIONS 
The selectivity of drugs towards the cancerous cells is one of the limiting factors in the 
application of current chemotherapeutic agents. The therapeutic window for the conventional 
anti-cancer drugs is low which implies that higher dosage would require inducing a certain 
therapeutic effect. This raises the concerns about off- target toxicity. Drug resistance is another 
problem during chemotherapy which mandates the application of combination therapy or 
increased dosage of the drug. In order to suppress the chemotherapy- related problems, various 
nanomedicine systems such as, micelle and drug polymer conjugates have been developed where 
a plethora of research interests have been directed towards nanoparticles due to their 
extraordinary properties such as their high surface to volume ratio, their favorable safety profile, 
their tendency to cross cellular barriers and their flexibility in surface functionalization by 
moieties for targeted applications. An emerging application of nanoparticles as “theranostic” 
agents, the marriage of therapy and diagnostics, further entices scientists to delve into their 
unique properties as they offer advanced capabilities in a single platform. Despite the promising 
properties of nanoparticles, their translation from bench to bedside is not a trivial issue and 
requires extensive characterization in terms of biocompatibility, pharmacokinetics, 
reproducibility and real time monitoring of the drug release [162]. Towards this end we adopted 
a facile green route where we moved away from harshly chemical synthetic modifications to 
obtain our pristine carbon nanoparticle. The carbohydrate source was chosen as agave nectar 
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which has a high fructose and glucose level further ameliorating the safety issues relevant to 
nanoparticle toxicity. In the next step, we adopted a facile approach for the introduction of CB[6] 
on CNP surfaces because it was predicted that the physio-absorption would anchor CB[6] on the 
surface CNP through hydrogen bonding. In the final step, Nic as the cancer stem cell targeting 
therapeutic was introduced to the system through non covalent interaction. The overall adopted 
procedure is demonstrated schematically in Figure 3.1. 
 
 
Figure 3. 1 (a) The particles were prepared by two methods i.e. either post functionalized (left) or pre functionalized 
(right); niclosamide was introduced to both particles subsequently by vortexing; (b) The CNP coated with CB[6] 
loaded with STAT3 inhibitor (niclosamide) can effectively target cancer stem cell and lead to cell apoptosis. 
 
It is important to determine the hydrodynamic size of the nanoparticles for systemic 
applications as it directly influences the nanoparticles accumulation and clearance profile from 
(a) 
(b) 
37 
 
body. Therefore, dynamic light scattering measurements were carried out for pristine and 
functionalized particles. Initially, the hydrodynamic size of the prepared carbon nanoparticles 
decorated with CB[6] was optimized by making various dilutions of CB[6] while keeping the 
CNP content constant. The ultimate goal was to reach a monolayer of CB[6] on the top of the 
nanoparticles. As can be seen in Figure 3.2 the concentration of CB[6]=10-3 mM yielded the 
optimum hydrodynamic size whilst further dilution of CB[6] resulted in no significant size 
variation implying the optimal condition. Hence, the concentration of CB[6] was set to 10-3 mM 
in the rest of the experiments. 
 
Figure 3. 2 Optimization of the hydrodynamic diameter through serial dilution. 
 
Two methods were adopted for the preparation of CB[6] decorated CNPs. The hydrodynamic 
size obtained by the methods was compared using dynamic light scattering. The mean 
hydrodynamic size for CNP, CB[6] CNP post functionalized and pre functionalized samples was 
determined to be 76±13, 93±4 nm and 55±1 nm, respectively (Figure 3.3a). The small size 
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difference between CNP and CB[6] coated samples showed that CB[6] did not appreciably affect 
the size and presumably resulted in the formation of single layer coating. Similarly, the 
anhydrous size diameter was determined after 100 random measurements through TEM analysis 
and it was revealed that the size was 88±22 nm and 31±6 nm for post and pre functionalized 
samples, respectively. As shown in Figure 3.3b, the discrepancy between hydrodynamic and 
anhydrous diameter was marginal suggesting the semi rigid nature of these particles. In fact, the 
hydrodynamic size is seen to be greater in the soft particles such as polymers which tend to 
entrap high water content in their structure; yet in the case of hard core particles the difference is 
negligible. The smaller size of prefunctionalized samples compared to post functionalized ones 
could be due to more controlled nucleation of CNPs in the presence of CB[6] as a result of 
confinement effects CB[6] exerts on CNP growth. 
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Figure 3. 3 (a) The hydrodynamic size comparison between CNP, CB[6] coated CNP pre and post functionalized, 
(b) the comparison between anhydrous and hydrodynamic size of the CB[6] coated CNP obtained by two method of 
synthesis.   
 
(a) (b) 
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One limitation associated with the applications of nanomaterials in biomedicine is their 
tendency to form agglomerate in high- ionic strength solutions such as biological media as a 
result of pronounced effect of particle functionalities. Therefore, it is of prime importance to 
investigate the nanoparticle size stability over extended period of time so as to avoid potential 
issues such as blockage of blood capillaries in vivo and elimination as foreign entities by 
reticuloendothelial system (RES) [163]. The stability of the nanoparticles was examined at 
various physiologically relevant media over the period of one month (Figure 3.4a-c).  
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Figure 3. 4 Stability profile based on hydrodynamic size monitored in the period of one month in (a) aqueous media, 
(b) aqueous low pH environment, (c) aqueous media containing 10% FBS. 
 
(a) 
(c) 
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The hydrodynamic size measurement revealed that particles were quite stable without 
any noticeable aggregation in aqueous media at neutral pH and aqueous media at pH 4.5 at 37 
ºC. Interestingly, the particles incubated in aqueous media containing 10% FBS also 
demonstrated a stable profile. FBS is a widely used serum in cell culture studies because it 
closely mimics the protein contents and properties of biological fluids [163]. It should be noted 
that the DLS size reading based on count criteria was hampered due to the masking effects of 
FBS macromolecules on size and instead the intensity criteria was chosen for size measurement 
in FBS containing media. This much of stability at various media can be attributed to the 
negative zeta potential values which result in particle repulsion and prevent aggregation.  
The morphology and size distribution of the nanoparticles are illustrated in Figure 3.5 a-
d. A bright halo ring around post functionalized samples clearly indicated the formation of 
uniform coating around CNP (Figure 3.5c). Furthermore, the particles prepared in the presence 
of CB[6] showed network formation into several clusters (Figure 3b, inset). This could be due to 
CB[6] assisted self- assembly as has already been pointed out for gold nanoparticles [164]. For 
our system, we hypothesized that the growth of CNP was possibly mediated through the binding 
of carbon atoms onto the carbonyl portal of CB[6] which glued the CNPs together. The particles 
were further characterized by AFM measurements (Figure 3.6) where the average height of both 
post and prefunctionalized samples were determined to be approximately 20 nm.   
 
 
 
 
41 
 
 
Figure 3. 5 Transmission electron micrographs of the prepared nanoparticles; (a) and (c) post functionalized CB[6] 
coated carbon nanoparticles, (b) and (d) pre functionalized CB[6] coated nanoparticles. 
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Figure 3. 6 Tapping mode AFM topographical images of (a) post and (b) pre functionalized carbon nanoparticles. 
 
In the next step, the electrophoretic potential of the pristine CNP and CB[6] CNP in the 
absence and the presence of Nic were determined by zeta potential measurements (Figure 3.7). 
The negative zeta potential on the surface of CNP (-29 ± 5 mV) represented the abundance of 
carboxyl, carbonyl, hydroxyl groups which contribute to the enhanced aqueous dispensability 
and stability of CNPs and would therefore facilitate the in vitro and in vivo applications In the 
presence CB[6], zeta potential values became slightly more positive both for postfunctionalized 
(-27±5 mV) and prefunctionalized samples (-19±9 mV) which is consistent with the surface 
charge on the outer surface of CB cavity carrying slightly positive charge [165]. Also, the 
addition of Nic further contributed to higher zeta potential values (-18±5 mV for drug loaded 
postfunctionalized, -20±4 mV for prefunctionalzed samples, respectively). This observation 
could be as a result of the electrostatic interaction of CB[6] and Nic and complexation event 
which masked the negatively charged groups on Nic and imparted a positive charge. However, 
the values still lied in the stable range and the electrostatic repulsive forces sustained the 
colloidal stability to prevent the agglomeration of CNP. This observation was further supported 
by the DLS measurements in various physiologically relevant environments over the course of 
one month. 
(a) (b) 
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Figure 3. 7 Electrophoretic potential (, surface charge (mV)) from zeta potential measurement. 
 
The UV-Vis spectra of CNP, Nic, CB[6] CNP pre functionalized, CB[6] CNP post 
functionalized sample in the absence and the presence of drug is shown in Figure 3.8a. The 
absorption band for CNP was seen to be monotonically increasing and was devoid of any band 
gap transition that is typical of amorphous carbon substrates. In fact, the peak at around 280 nm 
can be attributed to the n–π* transition of the C=O band and the π–π* transition of the 
conjugated C=C band. CB[6] did not show any UV-Vis signature peak due to the lack of 
conjugated moieties. Nic, on the other hand, showed UV-Vis spectrum which was dependent on 
the pH of the experiment. Figure 3.8b showed the effect of pH on the peak positions of Nic. Nic 
was barely soluble in water and low pH conditions while its solubility was greatly enhanced by 
increase in pH. At basic pH, Nic indicated four distinct peaks whereas in acidic or neutral 
conditions only two bands appeared which could be explained based on the resonance effects as 
well as the dissociation of phenolic- OH group to phenolate in base [58]. In addition, from Figure 
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3.8a it is evident that the addition of CB[6] resulted in dampening of Nic characteristic peaks 
confirming complexation between Nic and CB[6]. In the same vein, CB[6] CNP 
postfunctionalized samples also showed similar trend. Furthermore, UV-Vis studies on drug 
loaded particle were carried out. As can be seen (Figure 3.8a) the characteristic hump of Nic at 
377 nm was apparent in drug loaded CB[6] CNP particles and was mostly masked by the CNP 
spectrum. The tracking of the complexation between CB[6] and Nic is further elucidated by 
various titration methods which will be discussed in details in subsequent chapters.     
  
Figure 3. 8 UV-Vis spectra of (a) the individual components and their interactions (b) niclosamide at various pH. 
 
Vibrational spectroscopy is a powerful method in identifying the interaction between 
various components in the system. Figures 3.9a and b show the FTIR and Raman spectra of 
pristine CNP along with prefunctionalized and postfunctionalized samples with CB[6] in the 
presence and absence of Nic. Characteristic features of both Nic and CB[6] can be identified 
from both of the spectra. For the IR characterization, we focus on the C=O (1680 cm-1), AmideI 
(1550 cm-1), C=C, NO2 (symmetric and asymmetric) stretch for the Nic molecule. The 
(a) (b) 
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characteristic band assignment of CB[6] was also made as follows: 1732 cm-1 C=O [166], 3485 
cm-1 N-H [167], 1473 cm-1 C-N stretching vibration  [167] and 2930 cm-1 –CH2 stretching 
vibration [168].  
  
Figure 3. 9 (a) Infrared absorption and (b) Raman spectra of various formulations. In the Raman spectra of the CNP 
samples the D and G bands are taken as an indicator of the successful functionalization. 
 
Pristine CNPs had a variegated structure, which depended on the choice of synthesis precursors. 
CNPs displayed a variety of IR peaks including C=O and C=C vibrations. Upon CB[6] and/ or 
Nic introduction on the CNPs surface, features corresponding to both Nic and CB[6] can be 
identified. This is a proof of successful incorporation of the molecules on the CNPs surface and 
also confirmed the successful implementation of the synthetic strategy. To compare the synthetic 
(a) (b) 
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routes to functionalize the CNPs with CB[6] and Nic, the IR spectra of the products from the pre 
and post functionalized syntheses were investigated. While in the post functionalized samples, 
CB[6] and the Nic peaks can be easily identified, the CNP features were less distinct. On the 
other hand, in the pre functionalized samples, the CNP features overwhelm the vibrational peaks 
from Nic and CB[6].  
While the molecular vibrational features from each of the components (Nic and CB[6]) 
were distinct in infrared, the intense Raman features corresponding to the CNPs masked the 
contributions from the other passivating molecules. CNPS are interesting materials to be imaged 
by vibrational spectroscopy in biological settings. Therefore, they can be utilized as a platform 
for theranostics applications to track the distribution of drug inside the organisms and to optimize 
disease treatment  [162, 169]. The two characteristic bands of CNPs i.e. D and G bands are 
utilized to this end. The D band (sp3 hybridized) is often referred to as the disorder band or the 
defect band and is associated with the vibration of carbon atoms with dangling bonds in the 
terminal plane of the disordered graphite of amorphous carbon. The G band (sp2 hybridized), on 
the other hand, is related to the vibration of carbon atoms in a two dimensional hexagonal lattice 
[170]. The ratio of the two parameters was used as an indicator for the determination of the 
structure of CNPs. We identify the extent of passivation through the ratio of the G and D bands, 
which showed a considerable change with the change in the nature of the passivation. The 
change could be attributed to the collective addition of all the molecular vibrational features in 
the 1200-1400 cm-1 region which affected the intensity ratio.  
 3.2 TITRATION STUDIES 
A very critical parameter during complexation event is the binding constant which is indicative 
of the stability of the complex. The terms binding constant, stability constant and equilibrium 
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constant are interchangeably used in the context of host guest chemistry and are is determined 
via various analytical tools. In this research, we used UV-Vis spectroscopy, fluorescence 
spectroscopy, 1H NMR spectroscopy and cyclic voltammetry to investigate the complexation 
event between Nic and CB[6]. The rationale behind using various analytical methods originates 
from the fact that the host (H) guest (G) chemistry of CB[6] and Nic is unexplored and to the 
best of our knowledge this is the first study on this system. Titration studies were carried out 
utilizing these analytical techniques. In a typical titration investigation, the concentration of one 
component (i.e. either guest or host) was kept constant while the concentration of the other 
component was varied. To ensure the maintenance of the concentration in the titrant, a solution 
containing both host and guest is prepared where the concentration of host was 10-20 times 
greater than the host concentration. Therefore, upon the addition of aliquots of the titrant the 
concentration of host was gradually increasing whilst keeping guest concentration constant. A 
parameter such as absorption in UV-Vis spectroscopy or 1H NMR shift was tracked which was 
directly proportional to the concentration of [HG] complex. Finally, depending on the 
stoichiometry of the reaction, relevant kinetics and thermodynamics parameters were obtained.          
3.2.1 STOICHIOMETRY OF THE REACTION BY THE METHOD OF CONTINUOUS 
VARIATION 
In order to determine the stoichiometry of a reaction, the method of continuous variation was 
utilized where the molar fraction of one the components (i.e.  ) was varied between zero 
and one and the concentration of [HG] (which was tracked by one concentration dependent 
parameter) was plotted versus mole fraction. The maxima or minima of the graph (Job’s plot) 
determines the stoichiometry of the reaction. The constructed FT-IR Job’s plot is demonstrated 
in Figure 3.10b. While most of the vibrational modes corresponding to both Nic and CB[6] 
remained constant (Figure 3.10a), the amide II modes (C-N) shifted to lower energies at a 2:3 
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concentration ratio corresponding to CB[6] and Nic. A possible reason for this could be due to 
the favorable interaction between the Nic molecules when it is inside the cavity of CB[6]. 
However to ascertain these interactions ab-initio calculations are needed to be carried out.  
 
 
 
Figure 3. 10 (a) FTIR spectra for varying molar ratios of CB and Nic, (b) Job’s plot showing the 2:3 binding model. 
 
3.2.2 UV-VIS TITRATION 
Details of carrying out a proper UV-Vis titration have been delineated already. The absorption 
for the peak at 340-343 nm is plotted against the [CB]/[Nic] concentration (Figure 3.11 a-d). The 
experiment was attempted twice by different machines. However, the determination of binding 
constant was hindered due to the strong scattering on the part of CB[6]. It has to be mentioned 
that the threshold for the scattering effect is approximately at the [CB]/[Nic]=1 which suggests 
that the unbound CB species were not creating significant scattering issue and the excess of CB 
after the mentioned threshold seriously affected the determination of the parameters of interest.     
 
(a) (b) 
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Figure 3. 11 UV-Vis titration curves of Nic with CB[6] collected by two different machines (a) Horiba Aqualog 
Scanning Spectrofluorometer (c) GENESYS 10 UV-Vis spectrometer, (b) and (d) host guest interaction by 
measuring absorbance at the respective wavelength. 
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Figure 3. 12 The fluorescent titration of Nic with CB[6] observing the scattering pattern. The arrows indicate the 
increase in concentration of CB[6].    
 
     
     
     
     
     
     
51 
 
The same issue with strong scattering due to low insolubility of the system was encountered with 
fluorescent titration (Figure 3.12). Nic lacks inherent fluorescence properties and therefore might 
not be the best candidate for carrying out the fluorescent titration. As expected, the fluorescence 
titration experiment did not yield any interesting patterns, although a gradual and consistent 
upward shift in the scattering intensity pattern was noticed. Therefore, we assumed that NMR 
titration which is not affected by the scattering of CB[6] should help us revealing the nature of 
binding more appropriately.   
3.2.3 1H NMR TITRATION 
NMR is a very powerfulmethod for acquiring information regarding the mechanism and 
structural location of the complex formation in the supramolecular chemistry. For instance, it 
may reveal which protons are encapsulated and which ones are not. Specifically, guest protons 
resonances located within the CB[6] cavity would experience an upfield shift (lower ppm) due to 
shielding effects whereas the protons outside the CB[6] portal would shift slightly downfield 
(higher ppm) due to deshielding effects. Thus, changes in chemical shift of the drug resonances, 
together with changes in line width, give information on the location, orientation and the kinetics 
of the binding of a drug bound to CB[6]. 
First and foremost, the assignment of the peaks was made in Nic 1H NMR spectrum 
(Figure 3.13). The peaks obtained by experiment were compared with the results from the 
reported chemical shifts. The results are summarized in Table 3.1.The titration curves are shown 
in Figure 3.14. Interestingly, after the addition of 0.028 mM of CB[6], pronounced splitting and 
broadening was noticed in the characteristic Nic peaks. This can be associated with the presence 
of mixed magnetic species of Nic as a result of complexation with CB cavity. In other words, the 
species interacting with CB[6] are experiencing a different electronic environment as a result of 
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interaction while the uncomplexed species remained unaffected at lower concentrations. This 
observation virtually disappeared upon further addition of Nic suggesting the magnetic 
homogenization of the species. The titration revealed that the amide peak moved downfield. One 
explanation for this observation might be due to the keto-enol tautomerisation where the N-H 
bond can be replaced by more electronegative OH bond and therefore the corresponding peak 
shifted downfield and the Nic got stabilized upon encapsulation. In addition, the protons # 1, 5, 
16 and 17 were all shifted upfield suggesting encapsulation by CB[6] whereas proton #19 shifted 
downfield due to being sticking out from CB[6] cavity. The suggested orientation was further 
confirmed by molecular modelling energy minimized studies of the CB and Nic. The energy 
minimized orientation of the Nic in CB cavity is shown in Figure 3.15a-c. 
 
Figure 3.13 Peak assignments of niclosamide. 
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Table 3. 1 The observed chemical shift of the numbered protons and its comparison by the literature data. 
Proton 
# 
Observed Chemical Shift (ppm) Literature data [58] Multiplicity 
4  8.81 8.82 doublet 
1  8.42 8.45 doublet 
5 8.29 8.30 doublet of doublets 
16 7.08 7.10 doublet 
17 7.52 7.55 doublet of doublets 
19 7.98 7.97 doublet 
 
 
Figure 3. 14 The 1H NMR spectra of niclosamide (2 mM) in the (a) absence and presence of (b) 0.21, (c) 0.42, (d) 
0.62, (e) 0.81, (f) 1.00, (g) 1.18, (h) 1.36, (i) 1.54, (j) 1.71, (k) 1.88, (l) 2.04, (m) 2.20 equivalent of cucurbituril [6] . 
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Figure 3. 15 Possible energy minimized configuration of Nic in CB[6] cavity. (a) Perspective, (b) orthotropic and (c) 
front view. The colors white, red, blue and green correspond to hydrogen, oxygen nitrogen and chlorine 
respectively. 
 
(a) (b) 
(c) 
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Besides, it was seen that the peak at 3.33 which is attributed to water peak was shifted downfield 
(Figure 3.16). In fact, the first guest molecule that was proven to be encapsulated in hydrophobic 
CB cavity was water molecule [171]. Upon complexation, water molecule was released from the 
CB cavity and therefore, the peak moved downfield to the deshielded region. Similar behavior 
has been reported elsewhere [172, 173].     
 
Figure 3. 16 The downfield shift of water peak in 1H NMR titration in the presence of increasing CB[6] 
concentration. 
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3.2.4 PH TITRATION STUDIES 
One aspect of interest in macrocylic host molecules is their potential in modifying the effective 
pKa (acid dissociation constant) values of included guest. The pKa value is highly dependent on 
the affinity of host towards protonated or deprotonated forms of guest and can result in desirable 
shift of its acidity constant [174]. Especially, CB has shown enhanced efficiency in changing the 
pKa values compared to Cyclodextrin hosts due to their higher binding affinity and selectivity. 
This strategy has been utilized effectively in fluorescent dye tuning [175], assaying [176], 
sensing [177] and drug delivery [178]. For instance, the host induced pKa change is reported to 
improve the efficiency of the drug in harshly gastric acidic environment and protects the drug 
from premature dimerization and decomposition [178]. Upon encapsulation, there is a shift in 
pKa value and stabilization of the protonated form of a molecule through ion dipole interaction 
as has been observed in benzimidazole based molecules. The pKa shift can be associated with 
both hydrophobic cavity and carbonyl rim of CB such that the hydrophobic cavity dislikes the 
ionic species whereas he carbonyl rim favors cationic guests which enhances the charge transfer 
of the encapsulated guest. Therefore, the acidity or basicity of the guest in CB cavity is 
predominantly determined by the host guest interaction. The shift in the acidity of a complex is 
in upward direction for weakly basic molecules as CB tends to act as a cation receptor while the 
opposite trend is expected for anion receptor host molecules [179].  
Nic is a weak acid with an estimated pKa value of 5.6 due to the presence of phenol 
groups. At pH 7.4, the most stable species of Nic are in the deprontonated form [180]. Upon 
encapsulation of Nic in CB cavity the deprotonated species become more stable therefore 
decreasing the pKa value (Figure 3.17).    
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Figure 3. 17 UV-Vis absorbance of Nic at 370 nm at various pH in the absence and presence of CB[6]. 
 
3.2.5 CYCLIC VOLTAMMETRY 
 
Various human diseases including different types of cancer are associated with redox imbalances 
and oxidative stress. It is well known that the ROS level varies in cancerous cells compared to 
the normal cells due to the accelerated metabolism. Redox modulating compounds exploits the 
present redox condition of the abnormal cells to their advantage as anti- cancer drug where they 
catalyze the oxidation of the redox- sensitive thiol- containing proteins and enzymes which will 
lead to cell apoptosis [181]. Nic is known to elevate the ROS level in Acute Myelogenous 
Leukemia Stem Cells without targeting the normal bone marrow [70]. Therefore, it is of interest 
to investigate the electrochemical behavior of Nic in the absence and in the presence of CB 
which would ultimately result in the de/modulation of biological activity.  
In general, the Redox conversions on the guest and host usually lead to significant 
changes in the stability of the host and guest complex. Upon encapsulation, the negatively 
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charged carbonyl rim can potentially interact with positively charged species thereby, stabilizing 
the protonated form of a molecule through ion dipole interaction. The cyclic voltammogram of 
Nic in the absence and in the presence of increasing amount of CB is shown in Figure 3.18. The 
Redox behavior of Nic is quite well established in literature. It is evident that the nitro group in 
Nic is irreversibly reduced to N- phenylhydroxylamine during which four electrons/ proton 
transfer occurs [182]. The current diminished upon CB[6] inclusion which shows the smaller 
diffusion coefficient than the free Nic and stabilization of the guest molecule (Figure 3.18). On 
the other hand, though, the cathodic potentials peaks were supposed to move to more negative 
values due to the hindrance of electron transfer posed by CB[6] encapsulation. However, our 
observation does not follow the expected trend. This trial narrowly investigates the effect of Nic 
complexation and therefore future experiments are required to pave the path for future studies on 
the electrochemical behavior of the developed formulation for forthcoming in vitro and in vivo 
applications.   
 
Figure 3. 18 The cylic voltagramm of Nic in the absence and presence of 3 equivalent of CB[6]. 
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3.3 IN VITRO RELEASE STUDIES 
The loading efficiency of CB[6], Nic was evaluated using the calibration curves. The loading 
efficiency was calculated to be 25±2%. Subsequently, the release of Nic fromCB[6] was 
determined under various conditions. To quantify the release at different time points, the 
calibration curve presented in Figure 3.19 was used where the absorbance at 339 nm was used to 
carry out the calculations. The release curve in aqueous media at room temperature and 37 ºC 
and aqueous media at pH 4.5 are shown in Figure 3.20a-c. The maximum percentage of drug 
release was observed to be around 5%. It was also seen that low pH did not exert favorable 
condition for the release of drug. The results suggest that aqueous media did not lead to 
significant release of drug. This results show the promise of the developed host guest complex 
for sequestering the drug as the cargo should not be released during systemic application and 
prior to reaching its target. However, as the MTT results rendered in the following chapter, the 
drug was efficiently released under in vitro condition leading to enhanced potency of the drug for 
both CB[6] Nic and CNP coated with CB[6].    
 
Figure 3. 19 The calibration curve used for determining the release profile. 
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The decreased release of the drug in low pH environment parallels with the pH titration 
observation where the shift in the titration curve was attributed to the stabilization of Nic in the 
presence of CB[6]. It should be mentioned that the kinetics studies were also attempted for CNP 
containing samples. However, the strong absorption of CNP along with the proximity of its peak 
to that of Nic hampered our quantification. Although, the results seem to be reasonable, further 
characterizations are under progress where we predict that the interference due to low solubility 
of Nic can be resolved. Furthermore, the release pattern should also be investigated in the 
presence of salt- containing environment which closely mimics the physiological conditions. 
This approach focuses on quantifying the bound drug instead of released drug. 
  
 
Figure 3. 20 The pattern of drug release for (a) aqueous media at room temperature (b) aqueous media at pH 4.5 at 
37 ºC and (c) aqueous media at 37 ºC. 
 
(a) (b) 
(c) 
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3.4 IN VITRO CELLULAR CYTOTOXICITY STUDIES 
In order to evaluate the growth-inhibitory effect of CB[6]-CNP-Nic nanoparticles MTT assay 
was performed. Experiments were performed in estrogen receptor (ER) positive MCF-7 cell line. 
Bright field imaging of treated MCF-7 cells revealed the loss of cell growth density and cellular 
morphology selectively in population treated with (Figure 3.21c) Nic; (Figure 3.21h) CB[6]-
CNP-Nic (post); (Figure 3.21i) CB[6]-CNP-Nic (pre) and (Figure 3.21e) CB[6]-Nic. On the 
other hand, (Figure 3.21b) CB[6]; (Figure 3.21d) CNP;  (Figure 3.21f) CB[6]-CNP (post) and 
(Figure 3.21g) CB[6]-CNP (pre) did not change cell growth density and cellular morphology  to 
any significant level compared to untreated MCF-7 cells (Figure 3.21a) itself. The MTT results 
showed that after 48 h incubation CNP, CB[6] and CB[6] CNP (post functionalized) did not 
induce any significant cytotoxic effect (Figure 3.j) for a range of used concentrations (from 1.5-
50 µM) which is a crucial and encouraging characteristic as a drug delivery platform and future 
biological applications. The IC50 value of Nic, CB[6] Nic and CB[6] CNP Nic (post 
functionalized) was determined to be (45±04)×10-6 M, (28±03)×10-6 M and (21±02)×10-6 M, 
respectively (Figure 3.21k). The enhancement in the inhibitory effect of Nic in the presence of 
CB[6], emphasizes the facilitated Nic delivery using the host chemistry of CB[6] and the 
incorporation of CNP enhanced it further to improve host-guest interaction of CB[6] and CNP in 
reversible manner. It helps to incorporate and release Nic better in void of CB[6] during 
preparation of CB[6]-CNP when it is present on surface of CNP. This also can be attributed to 
the facile internalization and translocation inside the cell, sustained release of drug and enhanced 
bioavailability of Nic in CB[6] Nic and CB[6] CNP Nic formulations compared to the small 
molecule form of Nic, which is sparingly soluble in aqueous medium. 
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Figure 3. 21 Cell toxicity assay in MCF-7 cells. Bright field imaging (a-i) were performed on cells treated for 48h 
with 25 μM of Nic concentration in various formulations or equivalent of CNP, CB[6] and CB[6]-CNP (a-i).  MTT 
assay was performed at Nic concentration ranging from 1.5 to 50 μM in various formulation form including CB[6]-
Nic, Nic and CB[6]-CNP-Nic (post) while CB[6], CNP and CB[6]-CNP were used as positive control. (k) MTT 
results were used to calculate IC50 values for Nic formulations and compared to evaluate the improvement in cancer 
cell growth regression efficiency.   
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CHAPTER 4 
CONCLUSION AND FUTURE OUTLOOK 
4.1 CURRENT PERSPECTIVE 
Herein, we reported on the successful synthesis of the novel carbon nanoparticles (CNP 
decorated with cucurbituril[6] (CB[6]) for the enhanced inhibition of cancer stem cells via 
targeting STAT3 pathway. The carbon nanoparticles were obtained from the environmentally 
benign hydrothermal synthetic route using Agave nectar as the carbohydrate precursor. The 
particles were either pre-functionalized or post-functionalized with CB[6] and were further 
loaded with STAT3 inhibitor Niclosamide (Nic). Comprehensive physiochemical 
characterization followed in order to confirm the successful synthesis of the novel 
nanoplatforms. Extensive studies including UV-Vis titration, 2D excitation- emission fluorescent 
titration, 1H NMR titration, pH titration and cyclic voltammetry, FT-IR were carried out to 
confirm the interaction as well as to examine the stoichiometry and possible binding behavior of 
CB[6] and Nic. Finally, the potential of the developed nanoformulations were evaluated in vitro 
by examining the drug loading and release kinetics studies, monitoring size stability over one 
month in physiologically relevant media and assessing the cell viability in MCF-7 cell line by 
MTT assay.        
The main findings can be summarized as follows: 
 The hydrodynamic size of CNP, CNP post and pre coated with CB[6] were determined to 
be 76±13, 93±4 nm and 55±1 nm, respectively. On the other hand, the anhydrous size for 
post and pre coated samples was found to be 88±22 nm and 31±6 nm respectively. The 
average height was measured to be approximately nm for post and pre coated specimens.  
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 The hydrodynamic size remained virtually unchanged in the aqueous media at pH=7 and 
pH=4.5 and in aqueous sample containing 10% FBS over the course of one month 
suggesting the suitability of the developed particles for in vitro applications. 
 The electrophoretic potential of the as synthesized CNP was circa -30 mV and varied 
depending on the chemical functionalization. However, the overall surface charge did not 
go beyond -18 mV, demonstrating the colloidal stability of the nanoparticles. This 
observation was compatible with the hydrodynamic stability of the particles.     
 The UV-Vis spectroscopy revealed the interaction between CB[6],Nic and CNP coated 
Cb[6] with Nic. 
 The presence of characteristic feature of CNP and CB[6] in the FTIR spectroscopy 
confirmed the success of synthetic strategy. Furthermore, through Raman spectroscopy 
the extent of surface functionalization was determined by tracking the intensity ratio of D 
and G band. 
 The constructed Job’s plot from tracking amide bond in FTIR revealed the 2:3 binding 
model. 
 Titration studies by UV-Vis and fluorescent titration were hampered due to poor 
solubility and the strong scattering effects of CB[6]. Therefore, it did not yield conclusive 
parameters such as binding constant.     
 The 1H NMR titration studies elucidated the mechanism of interaction of CB[6] and Nic 
and provided useful information on the drug orientation and the portal of entry in CB[6] 
cavity. 
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 Drug loading capacity of CB and Nic was 25%. The kinetics of release of Nic was 
examined under various physiological media and it was shown that Nic is not 
significantly being released over extended period of time suggesting its suitability for 
release only at the site of interest as has been observed through in vitro cell studies.  
 Approximately two fold enhancement in IC50 values were observed for the encapsulated 
drug vs free drug. The IC50 value of Nic, CB[6] Nic and CB[6] CNP Nic (post 
functionalized) was determined to be (45±04)×10-6 M, (28±03)×10-6 M and (21±02)×10-6 
M, respectively. Hence, this novel nanoplatform holds the promise for sustained and 
enhanced chemotherapeutic delivery of sparingly soluble niclosamide for modulation of 
stem cell signaling pathways.    
4.2 FUTURE OUTLOOK 
In this thesis, the in vitro characterization has been carried out for confirming the enhanced 
efficacy of Nic in the presence of Nano-Carbobitaceae. Further in vitro test such as DNA 
fragmentation by propidium iodide staining followed by FACS analysis and gel electrophoresis 
are ongoing to further elucidate the potential of the formulation for inhibiting cancer cell growth. 
Through these studies, mechanisms underlying the cell apoptosis will be investigated. 
Furthermore, the successful delivery of Nic as the cargo is going to be traced by FT-IR and 
Raman imaging modalities. In addition, animal studies are currently under progress to 
demonstrate the potential of the nanoplatforms for drug delivery purposes in vivo. 
 As part of our future plan, the nanoparticles are going to be incorporated within bio-
absorbable 3D printed esophageal stents for delivery of controlled doses of anti- neoplastic and/ 
or anti-inflammatory drug. The idea stems from the fact that the commercially available stents 
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come in narrow size options thus restricting their application. Therefore, towards “personalized 
stent” we will propose an translational engineering solution via the use of biodegradable shape 
memory polymers which directly targets the downsides of commercially available stents. The 
critical factor, though, is the choice of appropriate polymer matrix. In this case we propose the 
use of self-healing polymers which rivals its metallic base counterparts with the superiority of 
biodegradability. The polymer matrix is going to bear radio-opaque iodinated functionalities for 
accurate stent positioning guided through fluoroscopy. In our approach, another level of 
complexity is introduced and that is the sustained release of the anti- inflammatory drug from the 
polymeric matrix reservoir through a nanomedicine approach where we intend to combine the 
developed nano-carbobitace into our polymer for sustained release. Our multifunctional drug 
carrier is has also the potential of delivering controlled doses of anti- neoplastic therapeutics such 
as carboplatin, paclitaxel, cisplatin, fluorouracil. Most importantly, the architectural tuning of the 
polymer for personalized applications via 3D printing is going to be introduced for the first time. 
In this method, highly accurate, patient specific images of the esophagus and the tumor burden 
can be acquired by imaging modalities such as CT scanning and MRI. In the next step, 3D 
segmentation and visualization are going to be performed and a Computer-Aided Design (CAD) 
model of the segmented structures will begenerated. Ultimately, the proposed biodegradable 
shape memory polymer is printed layer by layer in an additive manufacturing scheme. Extensive 
materials and computational,and mechanical studies are to be conducted after the prototype 
development. Nevertheless, all the efforts would be meaningful only if the characterization of the 
system is made both in vitro and in vivo in a swine model guided by fluoroscopy.  
The project has a high potential for preclinical/ clinical translation.   
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